The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Aileron Therapeutics

Aileron Therapeutics (NASDAQ: ALRN) is a biopharmaceutical company developing and advancing a class of drugs called Stapled Peptides. The company's Stapled Peptides platform is a breakthrough approach to creating drugs for highly sought after biological targets using its peptide stabilizing technologies. Aileron's Stapled Peptides have demonstrated an ability to penetrate cells throughout the body and modulate intracellular and extracellular protein-protein interactions, critical control points for most human diseases. The ability to target and regulate these control points affords the opportunity to exploit potentially thousands of well characterized, yet currently "undruggable" cellular targets with applications in all human diseases.

Aileron Therapeutics Headquarter Location

285 Summer St

Boston, Massachusetts, 02210,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aileron Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aileron Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Aileron Therapeutics Patents

Aileron Therapeutics has filed 77 patents.

The 3 most popular patent topics include:

  • Proteins
  • Transcription factors
  • Clusters of differentiation
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Proteins, Macrocycles, Cell cycle, Clusters of differentiation


Application Date


Grant Date



Related Topics

Transcription factors, Proteins, Macrocycles, Cell cycle, Clusters of differentiation



Latest Aileron Therapeutics News

Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

May 19, 2022

Boston, Massachusetts, UNITED STATES Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicities Trial is evaluating ALRN-6924 as a treatment to prevent chemotherapy-induced neutropenia, other bone marrow toxicities, and toxicities outside of the bone marrow in patients with p53-mutated breast cancer being treated with doxorubicin plus cyclophosphamide and docetaxel (AC+D) AC+D is a highly toxic chemotherapy regimen, causing severe neutropenia in up to 75% of patients and alopecia in approximately 90% of patients Initial interim results anticipated in 4Q2022 Aileron to host a virtual KOL investor event today at 4:00 pm ET BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced it has treated the first patients in its Phase 1b randomized, controlled clinical trial evaluating ALRN-6924 to protect against chemotherapy-induced neutropenia and other bone marrow toxicities, as well as toxicities outside of the bone marrow in patients with p53-mutated breast cancer who are being treated with doxorubicin plus cyclophosphamide and docetaxel (AC+D). Nearly 1 million patients each year are diagnosed with a p53-mutated cancer in the US. Aileron is pioneering a precision medicine-based approach that is designed to enable the selective chemoprotection of healthy, normal cells in patients with p53-mutated cancers who are receiving chemotherapy without protecting their cancer cells from chemotherapy. “Dosing of the first patients in our Phase 1b trial in patients with p53-mutated neoadjuvant breast cancer is an important step in advancing our vision to bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy,” said Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer at Aileron Therapeutics. “The severe toxicity profile of AC+D will enable us to evaluate ALRN-6924’s protective effect against multiple chemotherapy-induced toxicities. Moreover, this breast cancer trial may potentially open an additional regulatory opportunity with established precedents for supportive care drug approvals.” AC+D, a standard of care for patients with neoadjuvant breast cancer, is a highly effective but also highly toxic chemotherapy regimen. It causes severe neutropenia in up to 75% of patients and alopecia in approximately 90% of patients. Aileron has previously presented non-clinical proof of mechanism data demonstrating ALRN-6924's ability to arrest cell cycling and protect against chemotherapy-induced toxicities in bone marrow stem cells (in vitro), epithelial gut mucosa cells (in vivo), and hair follicles and their stem cells (ex vivo). The company has also presented proof of mechanism data for cell cycle arrest in bone marrow stem cells and hair follicle cells in healthy human volunteers, and proof of concept data for reduced multilineage bone marrow toxicities in patients with small cell lung cancer (SCLC) treated with topotecan. About the ALRN-6924 Breast Cancer Trial Design The Phase 1b clinical trial will evaluate the safety, tolerability and protective effect of ALRN-6924 against hematologic toxicities and other toxicities in patients with neoadjuvant breast cancer. Anticipated to enroll 30 patients, the trial involves a parallel group design with a dose expansion cohort. Patients will receive doxorubicin plus cyclophosphamide (AC) on Day 1 of each 3-week cycle for 4 cycles, and then docetaxel (D) on Day 1 of each 3-week cycle for 4 cycles. In part 1 (Dose Evaluation), a control group of 8 patients with p53-wild type breast cancer (i.e., non-p53-mutated) will receive AC+D without ALRN-6924. Patients with p53-mutated breast cancer on the same AC+D regimen will be randomized to concurrently receive ALRN-6924 at 0.3 mg/kg ALRN-6924 (n=6) or at 0.6 mg/kg ALRN-6924 (n=6). ALRN-6924 is given as IV infusion on study days 0, 1 (day of chemotherapy) and 2. In Part 2 (Dose Expansion), 10 patients will receive the same AC+D regimen and the ALRN-6924 dose selected in Part 1. Upcoming ALRN-6924 Data Readouts In 4Q2022, Aileron anticipates reporting initial interim results from patients treated with AC in Part 1 of the breast cancer trial. In addition, the company anticipates reporting interim results from its ongoing Phase 1b randomized, double-blind, placebo-controlled clinical trial of ALRN-6924 in patients with non-small cell lung cancer undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors in June 2022 and topline results from that trial in 4Q2022. Virtual KOL Event Today Aileron will host a KOL investor event today, May 19, 2022, at 4 pm ET to highlight ALRN-6924’s revolutionary potential as the first precision medicine-based supportive care drug, the landscape and unmet need of chemotherapy-induced toxicities, and the company’s clinical development program and planned data readouts in 2022. For more details and to register, visit . About Aileron Therapeutics Aileron is a clinical stage chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives. ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, in which we exclusively focus on treating patients with p53-mutated cancers. Our targeted strategy is designed to selectively protect multiple healthy cell types throughout the body from chemotherapy without protecting cancer cells. As a result, healthy cells are spared from chemotherapeutic destruction while chemotherapy continues to kill cancer cells. By reducing or eliminating multiple chemotherapy-induced side effects, ALRN-6924 may improve patients’ quality of life and help them better tolerate chemotherapy. Enhanced tolerability may result in fewer dose reductions or delays of chemotherapy and the potential for improved efficacy. Our vision is to bring chemoprotection to all patients with p53-mutated cancers, which represent approximately 50% of cancer patients, regardless of type of cancer or chemotherapy. Visit us at to learn more. Forward-Looking Statements Statements in this press release about Aileron’s future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the potential of ALRN-6924 as a chemoprotective agent, the Company’s strategy and clinical development plans. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Aileron’s cash resources will be sufficient to fund its continuing operations for the periods anticipated or with respect to the matters anticipated; whether initial results of clinical trials will be indicative of final results of those trials; whether preclinical or clinical results will be indicative of results obtained in future clinical trials, including trials in different indications or with different chemotherapies; whether ALRN-6924 will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will be accepted by and warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether ALRN-6924 will receive approval from regulatory agencies on a timely basis or at all or in which territories or indications ALRN-6924 may receive approval; whether, if ALRN-6924 obtains approval, it will be successfully distributed and marketed; what impact the coronavirus pandemic may have on the timing of our clinical development, clinical supply and our operations; and other factors discussed in the “Risk Factors” section of Aileron’s annual report on Form 10-K for the year ended December 31, 2021, filed on March 28, 2022, and risks described in other filings that Aileron may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Aileron specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise. Investor Contact:

Aileron Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aileron Therapeutics Rank

  • When was Aileron Therapeutics founded?

    Aileron Therapeutics was founded in 2001.

  • Where is Aileron Therapeutics's headquarters?

    Aileron Therapeutics's headquarters is located at 285 Summer St, Boston.

  • What is Aileron Therapeutics's latest funding round?

    Aileron Therapeutics's latest funding round is IPO.

  • How much did Aileron Therapeutics raise?

    Aileron Therapeutics raised a total of $172.31M.

  • Who are the investors of Aileron Therapeutics?

    Investors of Aileron Therapeutics include Novartis Venture Funds, Apple Tree Partners, Lilly Ventures, Excel Venture Management, SR One and 5 more.

  • Who are Aileron Therapeutics's competitors?

    Competitors of Aileron Therapeutics include Sorrento Therapeutics, Amnis Corporation, Inotek Pharmaceuticals, IntelligentMDx, PTC Therapeutics and 13 more.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.


eSionic, formerly Zettacore, enables devices and systems that consume less materials, generate less waste, have longer life, operate with higher reliability, use less energy, integrate seamlessly, operate more efficiently and cost less.

Gahaga Biosciences

Gahaga Biosciences was founded in 2006 to commercialize a method for the isolation of stem cells from placental and umbilical tissues to be used in basic research. Gahaga Biosciences intends to provide stem cells to the research and commercial markets which are valued as a potential source of a range of types of tissue. Many scientists say embryonic stem cells are generally more versatile than adult cells, although they continue to explore the possibilities of adult stem cells. The company believe that placental and umbilical stems cells are an ideal model system for conducting basic research on cell differentiation and regulation. Gahaga Biosciences seeks to supply researchers with materials to focus on the basic mechanisms of stem cell differentiation - how stem cells make the decision to move from their stem cell state into a more committed phenotype. Gahaga also seeks to exploit the company's experience in other methods such as pancreatic islets.

Innovate Technologies In Biological System

Innoprot tGFP-BACE1 HEK293 Cell Line CB2 Internalization Assay Cell Line hGR Nuclear Translocation Assay Cell Line Human Cardiac Myocytes Assay Development Neurotoxicity Assay induced by beta amyloid NEWS Innoprot has been awarded on the Bizkaia Ekinez Prizes 05/06/2009 Innoprot has been awarded on the Bizkaia Ekinez Prizes with the "Gaztedi Prize"

Armgo Pharma

Armgo Pharma is a biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular, and neurological disorders. The company's proprietary drugs, known as rycals, are a new class of oral agents that act on a novel therapeutic target, the ryanodine receptor/calcium release channel (RyR) located on the sarcoplasmic/endoplasmic reticulum of the cell. Rycals act to stabilize these channels and repair the calcium leak caused by stress associated with chronic diseases. It is hypothesized that the leak in the RyR channels, if left untreated, may contribute to disorders affecting the heart, skeletal muscle, and the brain.


Invivo Sciences technology aims to bridge the gap in preclinical research performed using animal models and cell culture systems. Per the company, the advances in lab-automation coupled with the company's expertise in tissue engineering allows InvivoSciences to commercialize fast, reliable, and cost effective screening systems.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.